The denial of a preliminary injunction removes the most imminent threat to Stryker's OptaBlate BVN commercial launch; near-term revenue from the product can proceed. However, the underlying patent case remains pending and could result in a future damages award or post-trial injunction if Boston Scientific ultimately prevails. Traders should monitor the upcoming claim construction hearing in the district court as the next key catalyst.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 18 $307.80entry
- T+1 · 5mo ago −1.01%α −0.70% · $304.69
- T+5 · 5mo ago +8.09%α +10.47% · $332.71
- T+20 · 4mo ago +3.68%α +4.31% · $319.14
- T+60 · 2mo ago −8.54%α −9.97% · $281.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
On June 17, 2026, the Federal Circuit affirmed the District of New Jersey's denial of Boston Scientific's motion for a preliminary injunction against Stryker regarding the OptaBlate BVN product. The appellate court found no abuse of discretion in the lower court's conclusion that Boston Scientific failed to show a likelihood of success on the merits of its induced infringement claims against Stryker, at least at this preliminary stage. The ruling removes an immediate threat of an injunction blocking Stryker's product launch, which is a clear positive for Stryker but does not resolve the underlying patent litigation, which continues in district court with a scheduled claim construction hearing.
Court Ruling Details
Key Facts
- Stryker won affirmance of the denial of a preliminary injunction; the Federal Circuit found no abuse of discretion by the district court.
- Boston Scientific's request to enjoin Stryker's OptaBlate BVN product from market launch was denied at both the district and appellate levels.
- The ruling was based on substantial questions regarding whether Stryker induces infringement under the district court's tentative claim construction of the term 'reaches' in the '166 patent.
- The underlying patent case (2:25-cv-12700) is still active; a formal claim construction hearing is scheduled before Judge Evelyn Padin in the District of New Jersey.
- Costs of the appeal were awarded to Stryker.
Financial Impact
Preliminary injunction denied, Stryker is free to continue marketing and selling the OptaBlate BVN product while the patent case proceeds. No monetary damages were awarded.
Risk Factors
- Stryker could lose on the merits at trial in the district court, leading to a permanent injunction and/or damages award.
- A final claim construction adverse to Stryker could shift the infringement analysis and settlement leverage.
- Boston Scientific may seek emergency relief from the Federal Circuit en banc or from the Supreme Court, though unlikely given the interlocutory nature of the appeal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1agfa85l-SYK |
Track record
29 reports on SYK
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +23.40% at T+20 after the Oct 7, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 12, 20266d ago Court Ruling Neutral 3/10 Entry $309.64 Now $310.72 +0.35% settles Dec 14
- Nov 9, 20268d ago 8-K Neutral 2/10 Entry $324.29 Now $310.72 −4.18% settles Dec 9
- Nov 5, 202612d ago 144 Neutral 3/10 Entry $325.87 Now $310.72 −4.65% settles Dec 7
- Nov 4, 202613d ago S-3ASR Neutral 3/10 Entry $335.08 Now $310.72 −7.27% settles Dec 4
- Nov 3, 202614d ago Institutional Cluster Mixed 3/10 Entry $310.55 Now $310.72 +0.05% settles Dec 2
- Oct 29, 202619d ago 8-K Bearish 6/10 No price data
- Oct 29, 202619d ago Press Release Bearish 6/10 Entry $291.86 Now $310.72 −6.46% settles Nov 30
- Oct 26, 202622d ago Press Release Neutral 4/10 Entry $306.13 Now $310.72 +1.50% settles Nov 23
- Oct 20, 202629d ago PTAB Trial Bearish 5/10 Entry $297.60 Now $310.72 −4.41% settles Nov 18
- Oct 7, 20265w ago ANALYST-UPGRADE Bullish 4/10 Entry $275.25 to $339.65 Now $310.72 +12.89% ▲ +23.40% +24.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers